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Resumo 
 O presente trabalho descreve o estudo da actividade antimicrobiana de quarto 
derivados da quinoxalina N,N-dióxido: quinoxalina 1,4-dióxido, 2-metilquinoxalina 1,4-
dióxido, 6-cloro-2,3-dimetilquinoxalina 1,4-dióxido e 3-benzoil-2-metilquinoxalina 1,4-
dióxido contra as estirpes bacterianas Geobacillus stearothermophilus ATCC 10149, 
Escherichia coli ATCC 25922, Escherichia coli HB101, Escherichia coli (blaTEM, 
blaCTX-M) e Salmonella (blaCTX-M), assim como contra a estirpe de levedura 
Saccharomyces cerevisiae PYCC 4072. A determinação da concentração mínima 
inibitória (MIC) foi realizada pelo método de diluição. Os valores de MIC’s foram 
estimados para cada composto e estirpe. Os resultados obtidos sugerem potenciais 
novas drogas para quimioterapia. 
 
Abstract  
The present work reports the study of the antimicrobial activity of four 
quinoxaline N,N-dioxide: quinoxaline 1,4-dioxide, 2-methylquinoxaline 1,4-dioxide, 6-
chloro-2,3-dimethylquinoxaline 1,4-dioxide and 3-benzoyl-2-methylquinoxaline 1,4-
dioxide against Geobacillus stearothermophilus ATCC 10149, Escherichia coli ATCC 
25922, Escherichia coli HB101, Escherichia coli (blaTEM, blaCTX-M) and 
Salmonella (blaCTX-M) bacterial strains and also against the yeast Saccharomyces 
cerevisiae PYCC 4072. The determination of the minimal inhibitory concentration 
(MIC) was performed by the dilution method. The MIC values were estimated for each 
compound and each microorganism. The results obtained suggest potential new drugs 
for antimicrobial chemotherapy.  
 
1-INTRODUCTION  
Antimicrobial agents are largely used in treatment and prevention of 
microorganism infections. The misuse and the abusive use of this kind of drugs, in 
human health, veterinary and animal production [1,2], led to the development, of drug-
resistant and multidrug-resistant (MDR) microorganisms. In addition, the permanent 
contact with some antimicrobial drugs allows the development of allergies and 
respiratory complications, which are affecting the human population worldwide [3 – 6]. 
These conditions are becoming emergent public health issues in the sense that they 
compromise pharmacological activity and the use of these antimicrobial agents [7, 8].  
Because MDR bacteria are increasing worldwide [9, 10] human kind deals with the 
urgent need of development of new drugs with enhanced antimicrobial activity able to 
fight pathogens with no adverse effects.  
Quinoxalines and their poly-functional derivatives have been largely studied, in the 
latest years, namely in what regards to its medical and pharmacological applications [11 
– 18]. These studies point to chemotherapeutical interests regarding the anti-tumor, anti-
bacterial, anti-fungal, and anti-viral including anti-HIV [19-26] applications of these 
compounds. The quinoxaline derivatives with N-oxide and N,N-dioxide have particular 
interest once they present relevant anti-oxidant activity.  
E. coli bacteria is a commensally inhabitant of the vertebrates gastrointestinal gut and 
may also be found in common urinary infections, in neonatal meningitis, diarrhea and 
dysentery caused by pathogenic E. coli strains, especially in third world countries [27, 
28]. Resistant E. coli is also a concerning problem in the more developed countries in 
the sense that they have developed mechanisms by which they are able to destroy the 
antimicrobial agent by enzymatic action. The acquisition of β-lactamases with extended 
spectrum (ESBL) activity genes (bla) is a worldwide concerning problem [7, 8]. 
Infections caused by Enterobacteria may be asymptomatic but generally they cause 
small complications or symptoms and, in extreme situations involving virulent strains, 
may be fatal [29].  
In the present study four quinoxaline derivatives were tested (Table 1) for their 
antibacterial and antifungal activity: quinoxaline 1,4-dioxide (QNX), 2-
methylquinoxaline 1,4-dioxide (2METQNX), 6-chloro-2,3-dimethylquinoxaline 1,4-
dioxide (2,3METCLQNX) and 3-benzoyl-2-methylquinoxaline 1,4-dioxide 
(2METBQNX).  
 
Table 1. Quinoxaline derivatives N,N-dioxide  
Quinoxaline 1,4-
dioxide  
2-methylquinoxaline 
1,4-dioxide  
6-chloro-2,3-
dimethylquinoxaline 1,4-
dioxide  
3-benzoyl-2-
methylquinoxaline 1,4-
dioxide  
  
  
  
  
 
The activity of these compounds was tested against bacteria and yeast in order to 
understand the biological activity in both prokaryotic and eukaryotic models. Bacteria 
standard strains used in this study included Gram-negative and Gram-positive 
microorganisms E. coli ATCC 25922 and G. stearothermophilus ATCC 1014 
respectively.  
Regarding E. coli, besides the standard strain ATCC 25922 it was also included in this 
study two genetic variants: E. coli HB101, strain widely used for biotechnology and 
academic proposes exhibiting genetic resistance to streptomycin, and E. coli (blaTEM, 
blaCTX-M), a genetically modified resistant strain harbouring two distinct ESBL genes 
TEM and CTX-M enzymes genes, blaTEM and blaCTX-M respectivlly. It was also 
used a clinical isolate, Salmonella (blaCTX-M).  
 
2 – RESULTS AND DISCUSSION:  
2.1 –Gram-positive Bacteria  
The four quinoxaline derivatives were tested against G. stearothermophilus 
ATCC 10149. The results presented in Table 2 show that QNX and 2METQNX exhibit 
inhibition for concentrations between 1 and 3µg/µL. For 2,3METCLQNX, no inhibition 
was observed in concentrations under 6µg/µL. 2METBQNX presents inhibition at 
concentrations under 1 µg/µL.  These results evidence the antibacterial activity of the 
four quinoxaline derivatives against this standard strain. 
 Table 2. Antimicrobial activity of the quinoxaline derivatives against Gram-positive G. 
stearothermophilus ATCC 10149  
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2METQNX 42 50 36 22 NI 
2,3METCLQNX 24 26 12 10 NI 
2METBQNX 34 32 30 28 22 
 
2.2 –Gram-negative Bacteria  
The results obtained for the Gram-negative bacteria studied are presented in 
Table 3. For Gram-negative microorganisms, 2,3METCLQNX and 2METBQNX have 
no influence on normal bacteria growth. In fact, only 2,3METCLQNX exhibited growth 
inhibition against E. coli HB101. For QNX and 2METQNX, growth inhibition was 
observed only for concentrations under 3µg/µL, except for QNX tested against E. coli 
ATCC 25922 and E. coli HB 101, that revealed inhibition of growth for concentrations 
under 1µg/µL. Analysing the results, we may assume that three of the quinoxaline 
derivatives tested induct Gram-negative growth inhibition.  
 
Table 3. Antimicrobial activity of the quinoxaline derivatives against the Gram-
negative Bacteria 
 
   C o n c e n t r a t i o n  ( µ g / µ L ) 
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QNX 30 36 18 16 12 
2METQNX 22 28 16 12 NI 
2,3METCLQNX NI 
2METBQNX NI 
E. Coli HB 101 
QNX 52 46 42 -- 40 
2METQNX 42 36 36 28 -- 
2,3METCLQNX 28 26 18 14 NI 
2METBQNX NI 
E. coli (blaTEM, 
blaCTX-M) 
QNX 24 28 22 18 NI 
2METQNX 22 22 15 12 NI 
2,3METCLQNX NI 
2METBQNX NI 
Salmonella 
(blaCTX-M) 
QNX 26 34 18 14 NI 
2METQNX 16 28 18 12 NI 
2,3METCLQNX NI 
2METBQNX NI 
 
2.3 –Yeast strain  
According to the results obtained, the four quinoxaline derivatives tested do not 
present growth inhibition against S. cerevisiae for the concentrations tested in this 
study. The higher concentration was of 24µg/µL.  
 
2.4 –Ampicilin  
Ampicilin (AMP) was used as a control, once it is a recurrent antibacterial drug 
prescribed for bacterial infections. The inhibition zone obtained for a solution with 
25µg/µL is represented Table 4.  
 
Table 4. Antibacterial activity of ampicilin (AMP) at a concentration of 25µg/µL.  
Bacteria  Inhibition Zone/mm 
G. Stearothermophilus ATCC 10149  54 
Escherichia Coli ATCC 25922  24 
E. Coli HB101  26 
E. coli (blaTEM, blaCTX-M) N I 
Salmonella (blaCTX-M) N I 
 
 
2.5 – MIC determination  
There was no growth of the strains studied at concentrations over 3 µg/µL (Table 
5), except for 2,3METCLQNX tested against G. stearothermophilus, in agreement with 
the results obtained by the plate diffusion method.  
 
Table 5. Minimal inhibitory concentration (MIC) obtained by dilution method  
 QNX  2-METQNX  2,3-METCLQNX  2-MET-3-BQNX  
G. Stearothermophilus ATCC 10149  < 1.5 µg/µL  < 3 µg/µL  < 7,5 µg/µL  < 1.5 µg/µL  
E. Coli ATCC 25922  < 1.5 µg/µL  < 1.5 µg/µL  N I  N I  
E. Coli HB101  < 3 µg/µL  < 1.5 µg/µL  < 1.5 µg/µL  N I  
E. coli (blaTEM, blaCTX-M) < 3 µg/µL  < 1.5 µg/µL  N I  N I  
Salmonella (blaCTX-M) < 1.5 µg/µL  < 1.5 µg/µL  N I  N I  
 
Quinoxaline and its derivatives are an interesting family of heterocyclic compounds, 
once they present a structure with similarity with quinolones, which present anti-
microbial activity [30]. In this study, it was patent a selectivity between bacteria and 
yeast.  The quinoxaline derivatives studied have presented activity against bacteria, but 
no activity against the eukaryotic model, S. cerevisiea, at the concentrations used. Also, 
there was observed a relevant growth inhibition in resistant strains of bacteria E. coli 
(blaTEM, blaCTX-M) and Salmonella (blaCTX-M). These results might suggest the 
performance of more studies, in order to determine their potential use as anti-bacterial 
agents, of human and veterinary interest.  
Different quinoxaline derivatives revealed selective activity among the bacterial strains 
studied. This fact strength us to believe that the mechanism involved in anti-bacterial 
activity of the quinoxaline derivatives studies may be related to the cell wall structures. 
The substituting groups presented in the quinoxaline structure reveal different activity 
against bacteria, that might be related to their electron donor or electron withdrawing  
comportment. 
 
3 - CONCLUSION:  
The compounds studied presented growth inhibition against Gram-positive 
bacteria (Figure 1). 2METQNX is the compound with a smaller inhibition zone, and the 
only one with electron donor characteristics. The two electron acceptors 
2,3METCLQNX and 2METBQNX present greater inhibition zones. It was observed an 
increase in the inhibition zone as we have compounds with withdrawing characteristics. 
All quinoxaline derivatives present a smaller inhibition zone, for the same 
concentration, when compared with ampicilin, so it may indicate that these compounds 
present no advantage of use against Gram-positive strains. 
 
 
Figure 1. Inhibition zone of the four quinoxalines tested and of ampicillin (AMP) 
against G. Stearothermophilus 
 
The activity against Gram-negative bacteria seems more selective. QNX and 
2METQNX present growth inhibition for all the bacteria tested (Figure 2). E. coli HB 
101 seems more sensible to these drugs and, in all species, the activity of 2METQNX is 
smaller than for QNX. These facts may be related with the presence of one –CH3 
electron donor group in this compound. On the other hand, 2,3METCLQNX and 
2METBQNX have groups with antagonistic characteristics and, curiously, they have no 
influence on the growth of Gram-negative bacteria, except for E. coli HB 101, that is 
inhibited by 2,3METCLQNX. When compared with AMP, Gram-negative bacteria E. 
coli ATCC 25922 and E. coli HB 101 present larger inhibition zones with the same drug 
concentration, for QNX and 2METQNX.  
 
 
Figure 2. QNX, 2METQNX and AMP at a concentration of 24 µg/µL activity against 
Gram-negative G. stearothermophilus 
 
All quinoxaline derivatives tested revealed no activity against S. cerevisiae at the 
concentration range tested, suggesting a potential use as antibacterial agents in humans 
since no eukaryotic damage appears to be observed, using this yeast as a reference 
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eukaryotic model. Naturally, further studies are needed to test the hypothesis. 
 
4 - EXPERIMENTAL:  
4.1 – Materials  
The culture media used were Trypton Soy Broth (Ref: 610058, LiofilChem, 
Italy), for liquid bacteria cultures, and Mueller-Hinton Agar (Ref: 422765, Oxoid, 
Basingstoke, UK), for solid bacteria cultures. The culture medium used for yeast 
cultures was YEPD (Oxoid, Basingstoke, UK). Ampicilin was obtained by Applichem 
(Ref: A0839,0100, AppliChem, Germany). E. Coli ATCC 25922 (Ref: 84204, 
LiofilChem, Italy) and G. stearothermophilus ATCC 10149 (Ref: 84248, LiofilChem, 
Italy) were obtained in pellet form. E. coli HB 101 was obtained from Bio – Rad 
Laboratories, CA, USA, E. coli (blaTEM, blaCTX-M) was transformed in our 
laboratories and results were confirmed by PCR technique [8] and Salmonella (blaCTX-
M) is a clinical isolate. S. cerevisiae PYCC 4072 was genteelly offered by Universidade 
Católica Portuguesa. All tests were performed at least three times, with 14 days interval 
between, in duplicate. Sterile blank disks with 6 mm diameter were used in every assay. 
 
4.2 – Quinoxaline compounds  
The four quinoxalines derivatives were synthesised and purified in previous 
thermochemical studies [22,31-36]. All the compounds were sublimed under reduced 
pressure for additional purification, before the tests performance. 
 
4.3 – Microorganisms culture and zone inhibition. MIC determination 
The bacteria and the yeast were sub-cultured according to Fernandes et al [7] 
and Prudêncio et al [10].Stock solutions with different concentrations (1, 3, 6, 12 and 24 
µg/µL) of the compounds were prepared and sterilised. Blank sterile disks were 
emerged in these solutions and poured over the prepared plates. Ampicilin (AMP) was 
used as standard drug.  
The MIC for each compounds/strain was estimated using the dilution method, according 
to the Clinical and Laboratory Standards Institute (CLSI, formely NCCLS) [37, 38].  
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